期刊
VIRUSES-BASEL
卷 13, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/v13112306
关键词
COVID-19; SARS-CoV-2; anti-viral screening; pseudovirus; spike protein; virus entry; virus attachment; virus post-attachment; pharmacophore
类别
资金
- Cystic Fibrosis Trust (UK) [CFTR F508del SRC]
- Punjab Educational Endowment Fund (PEEF)
A group of structurally-related compounds with moderate inhibitory activity against SARS-CoV-1 and SARS-CoV-2, acting early in the viral infectious cycle, were identified through screening FDA-approved compounds. These compounds have the potential for repurposing as antivirals for current and future coronavirus outbreaks.
Anti-viral small molecules are currently lacking for treating coronavirus infection. The long development timescales for such drugs are a major problem, but could be shortened by repurposing existing drugs. We therefore screened a small library of FDA-approved compounds for potential severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antivirals using a pseudovirus system that allows a sensitive read-out of infectivity. A group of structurally-related compounds, showing moderate inhibitory activity with IC50 values in the 2-5 mu M range, were identified. Further studies demonstrated that these kite-shaped molecules were surprisingly specific for SARS-CoV-1 and SARS-CoV-2 and that they acted early in the entry steps of the viral infectious cycle, but did not affect virus attachment to the cells. Moreover, the compounds were able to prevent infection in both kidney- and lung-derived human cell lines. The structural homology of the hits allowed the production of a well-defined pharmacophore that was found to be highly accurate in predicting the anti-viral activity of the compounds in the screen. We discuss the prospects of repurposing these existing drugs for treating current and future coronavirus outbreaks.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据